Incyte Drug Wins EU Approval for Hidradenitis Suppurativa
The European Commission approved Incyte’s once-daily oral drug Povofortay (povorcitinib) for eligible adults with moderate-to-severe hidradenitis suppurativa who cannot use or have not responded adequately to anti-TNF therapy. The approval was based on two Phase 3 trials that showed improved response versus placebo at 12 weeks; benefits persisted through 54 weeks, alongside improvements in pain, fatigue and quality of life. The company reported no new safety signals, with acne, nasopharyngitis and upper respiratory infections among the most common adverse events. The U.S. FDA is reviewing Incyte’s application for the same condition, with a potential approval and launch anticipated in the first quarter of 2027.
How it spread
Claim check
What each side asserts, disputes — or leaves out entirely.
Where do you land?
Whose framing of this story rings truest to you?







